Dataset Information

Clinical features of methamphetamine-induced paranoia and preliminary genetic association with DBH-1021C?T in a Thai treatment cohort.

ABSTRACT: To explore the clinical features of methamphetamine-induced paranoia (MIP) and associations between MIP and a genetic polymorphism in dopamine ?-hydroxylase (DBH-1021C?T).Retrospective analysis of clinical presentation and genetic association by ?(2) test and logistic regression analysis.A Thai substance abuse treatment center.A total of 727 methamphetamine-dependent (MD) individuals.Clinical: Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA) and the Methamphetamine Experience Questionnaire (MEQ). Genetic: DBH-1021C?T.Forty per cent of individuals (289 of 727; 39.8%) with MD had MIP. Within-binge latency to MIP onset occurred more rapidly in the most recent compared with initial MIP episode (P?=?0.02), despite unchanging intake (P?=?0.89). Individuals with MIP were significantly less likely to carry lower (TT/CT) compared with higher (CC) activity genotypes (34.3 versus 43.3%; ?(2) 1 ?=?5, P?=?0.03). DBH effects were confirmed [odds ratio (OR)?=?0.7, P?=?0.04] after controlling for associated clinical variables (MD severity, OR?=?3.4, P?

SUBMITTER: Kalayasiri R

PROVIDER: S-EPMC4018411 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Clinical features of methamphetamine-induced paranoia and preliminary genetic association with DBH-1021C→T in a Thai treatment cohort.

Kalayasiri Rasmon R Verachai Viroj V Gelernter Joel J Mutirangura Apiwat A Malison Robert T RT

Addiction (Abingdon, England) 20140317 6

<h4>Aims</h4>To explore the clinical features of methamphetamine-induced paranoia (MIP) and associations between MIP and a genetic polymorphism in dopamine β-hydroxylase (DBH-1021C→T).<h4>Design</h4>Retrospective analysis of clinical presentation and genetic association by χ(2) test and logistic regression analysis.<h4>Setting</h4>A Thai substance abuse treatment center.<h4>Participants</h4>A total of 727 methamphetamine-dependent (MD) individuals.<h4>Measurements</h4>Clinical: Semi-Structured A ...[more]

PMID: 24521142

Similar Datasets

Project description:BACKGROUND AND OBJECTIVE:Males and females who use methamphetamine (MA) differ in sociodemographics, MA diagnoses, comorbidities, and brain activity. The objective of this study was to investigate sex differences in the characteristics of MA use and dependence in patients at a Thai substance treatment center. METHODS:Demographic, MA use, and diagnostic data for 782 MA users were obtained by using the Semi-Structured Assessment for Drug Dependence and Alcoholism-Thai version. Categorical comparisons of males (n?=?413, 53%) and females (n?=?369, 47%) were made by chi-square test. Factors significantly differentiating men and women with respect to MA-dependence were identified by logistic regression analysis controlling for demographic, diagnostic, and MA use variables. RESULTS:Males admitted to residential drug treatment for MA use had an earlier age of onset for both MA use (17.7?±?4.1 vs 19.7?±?6.2 years; t?=?-5.3, P?<?0.001) and dependence (20.4?±?5.2 vs 22.2?±?6.4 years; t?=?-3.6, P?<?0.001). Females were more likely than males to be MA-dependent (79% vs 60%; ?1?=?33.7, P?<?0.001), and to experience MA withdrawal (65.3% vs 48.9%; ?1?=?21.4, P?<?0.001), withdrawal-related hypersomnia (77.2% vs 64.8%; ?1?=?14.5, P?<?0.001), fatigue (77.5% vs 70.3%; ?1?=?5.2, P?=?0.02), and psychomotor retardation (64.5% vs 57.0%; ?1?=?4.5, P?=?0.03). Similarly, females had heavier (eg, largest daily amount [?1?=?12.4, P?<?0.001), more frequent (?1?=?5.1, P?=?0.02]) and greater lifetime episodes of MA use (?1?=?24.1, P?<?0.001) than males. After controlling for such variables by logistic regression, being female remained a significant factor influencing the occurrence of MA-dependence (odds ratio [OR] 2.7, 95% confidence interval [CI] 1.8-4.1, P?<?0.001). Shared associated factors (or comorbidities) for MA-dependence in both sexes included nicotine dependence (in males: OR 4.1, 95% CI 2.4-7.0, P?<?0.001; and in females: OR 2.4, 95% CI 1.3-4.4, P?=?0.007), greater lifetime episodes of MA use (in males: OR 3.5, 95% CI 1.9-6.4, P?<?0.001; and in females: OR 5.9, 95% CI 3.1-11.4, P?<?0.001), and more frequent use (in males: OR 5.1, 95% CI 2.8-9.1, P?<?0.001; and in females: OR 3.6, 95% CI 1.9-6.9, P?<?0.001). Comorbid antisocial personality disorder predicted MA-dependence in males only (OR 3.7, 95% CI 1.6-8.6, P?=?0.002). CONCLUSIONS:The current study highlights both common (eg, nicotine dependence and severity of MA use) and sex-specific differences (eg, MA use/dependence characteristics and comorbidities), including sex itself, with respect to MA-dependence in a Thai treatment cohort.

Project description:BackgroundThe quinone oxidoreductase 1 (NQO1) gene was involved in the pathophysiological process of illicit drugs abuse, and its polymorphisms might be associated with methamphetamine (METH) dependence susceptibility. The purpose of this study was to examine the NQO1 mRNA and protein levels and to analyze the 609C/T polymorphism (rs1800566) between METH-dependent patients and controls.MethodsA total of 392 METH-dependent patients (cases) and 669 healthy controls (controls) were enrolled in the study. The quantitative real-time polymerase chain reaction (RT-qPCR) and enzyme-linked immunosorbent assay (ELISA) were used to detect the relative expressions of NQO1 mRNA in PBMCs and protein levels in plasma, respectively. PCR-restriction fragment length polymorphism (RFLP-PCR) and direct-sequencing genotyping were used to detect the alleles and genotypes of NQO1 609C/T polymorphism.ResultsThe levels of NQO1 mRNA in cases (3.2650 ± 2.2943) was significantly higher than in controls (1.0125 ± 0.7959) (p < 0.001), the plasma protein in cases (0.2368 ± 0.1486) was significantly lower than in controls (0.5844 ± 0.1742) (p < 0.001). The T allele of the 609C/T polymorphism significantly increased the risk of METH dependence (p = 0.032, OR = 1.214, 95%CI = 1.017-1.450). The TC and TC/TT genotypes of 609C/T were observed significantly more frequently in cases than in controls, respectively (TC vs CC: p = 0.012, OR = 1.457, 95% CI = 1.087-1.952; TC/TT vs CC: p = 0.008, OR = 1.460, 95% CI = 1.102-1.935). Similar results were obtained after adjusting for age and sex. We failed to find that any genotype of 609C/T polymorphism affected the mRNA or plasma protein levels in controls, respectively (p > 0.05).ConclusionThe findings suggested that NQO1 might play an important role in the pathophysiological process of METH dependence, and the 609C/T polymorphism might contribute to the susceptibility to METH dependence in a Chinese Han population.

Dataset Information

Clinical features of methamphetamine-induced paranoia and preliminary genetic association with DBH-1021C?T in a Thai treatment cohort.

Publications

Clinical features of methamphetamine-induced paranoia and preliminary genetic association with DBH-1021C→T in a Thai treatment cohort.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets